[{"id":"46872237-6ce2-4f9c-9626-78292d387d52","acronym":"CanStem111P trial","url":"https://clinicaltrials.gov/study/NCT02993731","created_at":"2023-11-15T19:14:20.299Z","updated_at":"2024-07-02T16:35:29.170Z","phase":"Phase 3","brief_title":"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT02993731 - CanStem111P trial","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 1134","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2023-11-15"},{"id":"657a150b-5f41-44b4-ab84-352d511b0114","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325441","created_at":"2021-01-18T05:23:55.341Z","updated_at":"2024-07-02T16:35:29.056Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT01325441","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 565","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2023-11-15"},{"id":"8a45fead-cf37-4fe6-b1b4-3275fc24166b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01776307","created_at":"2021-01-18T07:50:01.225Z","updated_at":"2024-07-02T16:35:29.131Z","phase":"Phase 2","brief_title":"A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT01776307","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab) • capecitabine • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2023-11-15"},{"id":"b12985dc-ad65-43ed-8d9c-667f21a6d1b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02024607","created_at":"2021-01-18T09:15:39.668Z","updated_at":"2024-07-02T16:35:29.143Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","source_id_and_acronym":"NCT02024607","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium • napabucasin (BBI608) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 495","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2023-11-15"},{"id":"d2aeb8e6-4453-4c46-8189-8e256a9cca01","acronym":"CO23","url":"https://clinicaltrials.gov/study/NCT01830621","created_at":"2021-01-18T08:08:24.045Z","updated_at":"2024-07-02T16:35:38.911Z","phase":"Phase 3","brief_title":"BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma","source_id_and_acronym":"NCT01830621 - CO23","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 05/10/2013","start_date":" 05/10/2013","primary_txt":" Primary completion: 05/07/2016","primary_completion_date":" 05/07/2016","study_txt":" Completion: 05/16/2016","study_completion_date":" 05/16/2016","last_update_posted":"2023-08-28"},{"id":"0aa17be4-1019-48c2-aae6-8e7c68526412","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522649","created_at":"2022-06-12T05:56:57.860Z","updated_at":"2024-07-02T16:36:58.810Z","phase":"Phase 3","brief_title":"A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03522649","lead_sponsor":"1Globe Health Institute LLC","biomarkers":" CTNNB1 • STAT3","pipe":"","alterations":" ","tags":["CTNNB1 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • napabucasin (BBI608)"],"overall_status":"Unknown status","enrollment":" Enrollment 668","initiation":"Initiation: 04/12/2018","start_date":" 04/12/2018","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-06-18"}]